AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Recent studies by K. Arasteh and co-authors add new data to HIV/AIDS findings
July 13th, 2009
In this recent report, researchers in Berlin, Germany conducted a study "To assess the efficacy and safety of a treatment switch from a twice-daily (BID) regimen containing zidovudine (ZDV) and lamivudine (3TC) plus a third agent to a once daily (QD) regimen containing the fixed-close combination of tenofovir DF/emtricitabine (TDF/FTC, Truvada (R)) plus a divergent third QD agent in HIV-1 infected patients. prospective, 48-week, non-randomised, single-group, open-label, study." "Fifty-one patients on stable ZDV/3TC-containing HAART, with HIV-1 RNA < 50 copies/ml and CD4+ T-cell count > 50 cells/mu l, were switched to TDF/FTC plus a third agent. Plasma HIV-1 RNA,...
Source: AIDS Weekly (2009-07-13)
|
